Last reviewed · How we verify
LY4152199 - IV
At a glance
| Generic name | LY4152199 - IV |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of LY4152199 in Participants With Previously Treated B-cell Cancers (BAF_FRontier-1 ) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |